echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > FIB-4 Index: It can predict the risk of liver cancer in patients with chronic hepatitis B after antiviral treatment

    FIB-4 Index: It can predict the risk of liver cancer in patients with chronic hepatitis B after antiviral treatment

    • Last Update: 2021-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    FIB-4 Index (Fibrosis 4 Score)?

    FIB-4 Index (Fibrosis 4 Score)?

    This is a non-invasive method for evaluating liver fibrosis in patients with chronic liver disease, because it does not require additional examinations, only a few values ​​on the physical examination sheet need to be substituted into the formula for calculation.


    medsci.


    FIB-4=Age×AST/PLT count×√ALT
    FIB-4=age×AST/PLT count×√ALTFIB-4=age×AST/PLT count×√ALTFIB-4=age×AST/PLT count×√ALT FIB-4=age×AST/PLT count× √ALT

    The critical value of FIB-4 index evaluation for different liver diseases is slightly different.


    1.


    1.


    The study included a total of 444 CHB patients who underwent liver biopsy and serological liver fibrosis marker testing.


    As a result, histological fibrosis staging has the highest predictive value for the risk of HCC at 5 and 7 years [area under the receiver operating characteristic curve (AUROC) 0.


    According to histological fibrosis stage (F4 vs.


    P

    2.


    2.


    The results showed that 40,729 people (32.


    FIB-4 index increased risks associated with severe liver disease diagnosis by FIB-4 index can identify about 5 0% of the future by cirrhosis of the liver affected people

    Researchers say it takes a long time to develop liver cirrhosis.


    3.


    3.


    A study recently published by National Taiwan University School of Medicine and National Taiwan University Hospital Tseng, etc.


    This retrospective multinational study included a total of 1936 CHB patients of different races and without cirrhosis.


    As a result, during an average follow-up of 6.
    98 years, a total of 48 patients developed HCC.
    The FIB-4 value at 1 year of treatment is significantly related to the risk of HCC, and the predictive value of the risk of HCC is better than the FIB-4 value before treatment.
    Stratified according to whether the FIB-4 value at 1 year of treatment was more than 1.
    30, compared with the low FIB-4 group, the risk of HCC was significantly increased in the high FIB-4 group (hazard ratio: 4.
    87, 95% confidence interval: 2.
    48 -9.
    55).

    Multivariate analysis showed that the patient’s gender and FIB-4 at 1 year of treatment were independent predictors of the risk of HCC.
    Among the 314 female patients with low FIB-4 at 1 year of treatment, there was no HCC.

    Finally, for patients with a low PAGE-B score, combined with whether the FIB-4 value at 1 year of treatment exceeds 1.
    30, the risk of HCC can be stratified.
    The PAGE-B score is <10, and the FIB-4 value at 1 year of treatment is < 1.
    30 patients have the lowest risk of HCC, and the annual incidence of HCC is only 0.
    11%.

    FIB-4 online use: medsci.
    cn/scale/show.
    do?id=c897264951" target="_blank" rel="noopener">FIB-4 index of liver fibrosis in patients with chronic liver disease

    medsci.
    cn/scale/show.
    do?id=c897264951" target="_blank" rel="noopener">FIB-4 Index of Liver Fibrosis in Patients with Chronic Liver Diseases FIB-4 Index of Liver Fibrosis in Patients with Chronic Liver Diseases

    references:

    Kim MN, Lee JH, Chon YE, et al.
    Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
    Eur J Gastroenterol Hepatol.
    2019 Sep 3.

    Hannes Hagström, Mats Talbäck, Anna Andreasson, Göran Walldius, Niklas Hammar.
    Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease.
    Journal of Hepatology, 2020; DOI: 10.
    1016/j.
    jhep.
    2020.
    06.
    007

    Tseng TC, Choi J, Nguyen MH, et al.
    One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment.
    Hepatol Int.
    2021 Feb;15(1):105-113 .



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.